Back to School: How biopharma can reboot drug development. Access exclusive analysis here

FDA lifts tgAAC94 hold

Targeted Genetics (TGEN) said FDA lifted the clinical hold on a Phase I/II trial of

Read the full 151 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE